toddski
1月前
Awesome. I remember talking to you a long time ago about WLDN, another undervalued stock.
Sanuwave for the most part looks like an amazing undervalued investment, besides their enormous debt. If they can R/S, capital raise or renegotiate debt on better terms, the stock will take off. Other things I like about the company - their consumables revenue is now surpassing their mist system revenue by a large margin, and that's recurring, higher margin revenue. Shows the customers who buy the mist systems are using them too. Youtube has some pretty great videos showing how the mist system works, and every review I've read has glowing reviews.
BadAttitude
5月前
Based on discussions with The Nasdaq Stock Market LLC (“Nasdaq”), SEP Acquisition Corp., a Delaware corporation (the “Company”), and SANUWAVE Health, Inc., a Nevada corporation (“SANUWAVE”), determined that the combined company was unlikely to be able to meet Nasdaq listing requirements and withdrew its listing application in order to submit an application to the Cboe BZX Exchange, Inc. This application is currently under review.
janeyH
8月前
On March 6, 2024, Sanuwave, Inc. entered into an exclusive license and option agreement (the “License and Option Agreement”) with a third party licensee (the “Licensee”) in connection with a portfolio of Sanuwave, Inc. patents related to the field of intravascular shockwave applications (the “Patents”). In exchange for a one-time payment of $2.5 million, Sanuwave, Inc. granted the Licensee an exclusive license to the Patents and an option to acquire the Patents for an additional one-time payment in the single-digit millions of dollars (the “License and Option Transaction”). If the Licensee does not exercise its option to acquire the Patents during a specified option period, the license terminates and all rights revert back to Sanuwave, Inc.
janeyH
9月前
Sanuwave Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
EDEN PRAIRIE, MN, January 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the Company is holding a special meeting of stockholders on February 21, 2024 at 10:00 a.m. CT (11:00 a.m. ET) to vote on the previously announced merger with SEP Acquisition Corp (“SEPA”).
Sanuwave announced on August 23, 2023 that the Company entered into an Agreement and Plan of Merger with Sweat Equity Partners and Mercury Life Sciences-affiliated SEPA. Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol “SNWV”.
The Company has commenced mailing proxy materials to stockholders to vote on proposals related to the merger with SEPA. Stockholders of record at the close of business on January 10, 2023 will be entitled to vote at the special meeting.
The Company’s board of directors unanimously recommends that stockholders vote “FOR” the merger proposal.
“Speaking for the Company and its board of directors, we’re all extremely excited about this transaction and see it as the freeing move to put the company upon a sound financial footing, simplify the capital structure, and to move up to the Nasdaq Capital Markets, said Sanuwave CEO Morgan Frank. “This will allow us to focus on rapid, profitable growth and to garner an equity valuation that reflects the performance of our business. My deep thanks to the Sanuwave team and all those who have helped us get here.”
janeyH
10月前
EDEN PRAIRIE, MN, Jan. 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (SNWV) (the "Company" or "SANUWAVE”) , a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the fourth quarter of 2023 are expected to be in the range of $6.6 to $6.8 million, an increase of 20% to 24% over Q4 2022. Fiscal year 2023 revenues are expected to be in the range of $20.0 million to $20.2 million, an increase of 19% to 20% over the fiscal year ended 2022.
“Q4 2023 was a record quarter of revenue for SANUWAVE driven by strength in the UltraMist product line. Consumables and in particular system sales saw accelerating growth as production constraints were overcome,” said CEO Morgan Frank. “We’re extremely pleased to have shown this level of growth year on year up against what had previously been the best quarter in SANUWAVE history in Q4 2022 and look forward to carrying this success on into 2024. The Company plans to release its full Q4 and annual results in late March and we look forward to speaking with you then to give you a more complete update on our quarterly and yearly performance and our future plans and guidance.”
The preliminary revenue results described herein are based on management’s initial analysis of the fourth quarter ended December 31, 2023, and may be subject to adjustments based on the Company’s completion of its year-end financial close process.
DrZSmith
1年前
Since approval, DP had never had legitimate momentum in the wound care space. The financials/sales validate that fact. Without competitive reimbursement and a solid business plan (which has never been present), it's impossible to obtain traction and be competitive. Moreover, there are multiple like players in this tech space with much better leadership, direction, and pricing. On the flip, Mist is old technology, breaks down easily, and no company has produced a new unit since Alliqua.
The bottom line is the low single is where SNWV stock will live until sold off.